California voters face a closely balanced decision on Proposition 38, an $8.4 billion general obligation bond for immunology and immunotherapy research that would allocate half the proceeds to a designated University of California-affiliated institute and the rest through competitive grants, with at least half directed to cancer, heart disease, and Alzheimer’s studies. Trader sentiment reflects support for accelerating medical breakthroughs against concerns over roughly $500 million in annual General Fund debt service for 25 years, potential tailoring of eligibility criteria for one nonprofit research center backed by major donors, and competition with other November 2026 bond measures for limited state borrowing capacity. Recent qualification for the ballot and public debate over policy design and returns have kept the contest tight, with shifts likely depending on polling trends, campaign spending on fiscal arguments, and broader voter views on research funding priorities before election day.